Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease (ESRD). The inhibitors of renin-angiotensin-aldosterone system (RAAS) can alleviate some of the symptoms of DN but fail to stop the progression to ESRD. Our previous studies demonstrate renoprotective action of nitro-oleic acid (OA-NO2) in several rodent models of renal disease. Here we examined the therapeutic potential and the underlying mechanism of combination of losartan and OA-NO2 in db/db mice. OA-NO2 was infused at 5 mg·kg(-1)·day(-1) via osmotic minipump, and losartan was incorporated into diet at 10 mg·kg(-1)·day(-1), each administered alone or in combination for 2 wk. Diabetic db/db mice developed progressive albuminuria and glomerulosclerosis, accompanied by podocytes loss, increased indexes of renal fibrosis, oxidative stress, and inflammation. Treatment of the diabetic mice with OA-NO2 or losartan alone moderately ameliorated kidney injury; however, the combined treatment remarkably reduced albuminuria, restored glomerular filtration barrier structure, and attenuated glomerulosclerosis, accompanied with significant suppression of renal oxidative stress and inflammation. These data demonstrate that combination of losartan and OA-NO2 effectively reverses renal injury in DN.
Univ. of Utah and Veteran Affairs Medical Center, Division of Nephrology and Hypertension, 30 N 1900 E, Rm. 4R312, Salt Lake City, UT 84132. tianxin.yang@hsc.utah.edu.
Ying
Y
Liu
Zhanjun
Z
Jia
Shanshan
S
Liu
Maicy
M
Downton
Gang
G
Liu
Yaomin
Y
Du
Tianxin
T
Yang
D000419:Albuminuria / Q000188:drug therapy; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D019808:Losartan / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D019301:Oleic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects
D047228:Angiotensin II Type 1 Receptor Blockers; D019301:Oleic Acid; D019808:Losartan
diabetic nephropathy; losartan; nitro-oleic acid; oxidative stress